Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Citryll","sponsor":"BOM Brabant Ventures","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Citryll Completes \u20ac 18.5 M Fundraise to Develop CIT-013, an Antibody Targeting Neutrophil Extracellular Traps","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Citryll"}]

Citryll

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Citryll Completes € 18.5 M Fundraise to Develop CIT-013, an Antibody Targeting Neutrophil Extracellular Traps

Details:

The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).

Lead Product(s): CIT-013

Therapeutic Area: Immunology Product Name: CIT-013

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: BOM Brabant Ventures

Deal Size: $21.0 million Upfront Cash: Undisclosed

Deal Type: Financing July 02, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY